Clinical and Paraclinical Characterization of Osseous Anomalies of the Long Bones of Patients With Klippel Trénaunay Syndrome

NCT07060703 | Active Not Recruiting

• 1 other identifier: 2023-A02765-40
• Study Type: interventional
• Target: 15
• Locations: 1 country
• Sites: 1

Brief Summary

Clinical and paraclinical characterization of osseous anomalies of the long bones of patients with Klippel Trénaunay syndrome

Conditions

Radiological Bone Phenotype Description of Patients With KTS ( Klippel-Trénaunay Syndrome )

Outcome Measures

Primary Outcomes (1)

• Quantification of limb-length asymmetry on lower-limb telemetry (absolute values, in mm) compared with the contralateral side

  The assessment of bone damage includes an X-ray of a weight-bearing pelvis and limb telemetry to detect any limb length abnormalities.

  20 minutes

Secondary Outcomes (4)

• description vascular of the KTS.

  30 MINUTES

• measurement of bone density (BMD) in the spine and femoral necks, with calculation of the FRAX index.

  20 MINUTES

• exploration of long bones using non-invasive Guided Wave Velocity (GWV) technology.

  20 MINUTES

• description vascular of the KTS.

  20 minutes

Study Arms (1)

Radiological Bone Phenotype Description of Patients With KTS

OTHER

Diagnostic Test: Osteodensitometry

Interventions

Osteodensitometry DIAGNOSTIC_TEST

exploration of long bones using non-invasive Guided Wave Velocity (GWV) technology. comparison of ultrasound parameters (cortical thickness and porosity, among others) with BMD values (spine, right and left femoral necks) obtained by DXA. \[Time Frame: 20 MIN\]

Also known as: non-invasive technology Speed of Guided Waves

Radiological Bone Phenotype Description of Patients With KTS

Eligibility Criteria

• Age: 7 Years+
• Sex: all
• Healthy Volunteers: No
• Age Groups: Child (0-17), Adult (18-64), Older Adult (65+)

You may qualify if:

• Vascular malformation such as Klippel-Trénaunay syndrome or Capillary malformations (CM) + venous malformations (VM) +/- Lymphatic malformations (LM) + limb overgrowth according to ISSVA (International Society for the Study of Vascular Anomalies) classification.
• Signature of study consent by subject of legal age or by 2 legal guardians for minors Patient affiliated to a social security scheme or beneficiary of such a scheme
• Age greater than or equal to 7 years

You may not qualify if:

• Pregnant or breast-feeding woman Protected person

Sponsors & Collaborators

• University Hospital, Grenoble: lead

Study Sites (1)

Chu Grenoble Alpes

La Tronche, 38700, France

Location

Study Officials

• SOPHIE M BLAISE, INVESTOGATOR

  University Hospital, Grenoble

  PRINCIPAL INVESTIGATOR

Study Design

• Study Type: interventional
• Phase: not applicable
• Allocation: NA
• Masking: NONE
• Purpose: OTHER
• Intervention Model: SINGLE GROUP
• Sponsor Type: OTHER
• Responsible Party: SPONSOR

Study Record Dates

• First Submitted: September 12, 2024
• First Posted: July 11, 2025
• Study Start: September 12, 2024
• Primary Completion: September 15, 2024
• Study Completion (Estimated): October 1, 2026
• Last Updated: July 11, 2025

Record last verified: 2025-03

Data Sharing

• IPD Sharing: Will not share

Locations

FR (1)